Skip to main content
. 2024 Feb 7;147(7):2414–2427. doi: 10.1093/brain/awae032

Figure 1.

Figure 1

CSF concentrations of SNAP-25, 14-3-3 zeta/delta (ζ/d), β-synuclein, neurogranin and NPTX2 (one representative peptide for each protein) across diagnostic groups. For visualization purposes only, P-values for comparisons, including the control or Alzheimer’s disease dementia (ADD) groups, are shown due to space constraints. All P-values from the group comparisons are shown in Supplementary Table 2. The bottom and top hinges of the box plot denote the 25th and 75th percentiles, respectively, while the medians are represented by vertical lines, and the whiskers extend to the most extreme points within the 1.5× interquartile range of the 25th and 75th percentiles. AD = Alzheimer’s disease; Aβ = amyloid-β; Aβ− CU = controls; Aβ+ CU = preclinical AD; Aβ+ MCI = prodromal AD; bvFTD/PPA = behavioural variant frontotemporal dementia/primary progressive aphasia; CU = cognitively unimpaired; DLB = dementia with Lewy bodies; MCI = mild cognitive impairment; non-AD = non-AD neurodegenerative diseases; PD = Parkinson's disease; PSP/MSA = progressive supranuclear palsy/multiple system atrophy; VaD = subcortical vascular dementia. P-values: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 and ****P ≤ 0.0001.